HXBM (Helix Biomedix) Cyclically Adjusted FCF per Share: $0.00 (As of Sep. 2012)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Helix Biomedix Cyclically Adjusted FCF per Share?

Helix Biomedix HXBM Cyclically Adjusted FCF per Share is $0.00 as of Sep. 2012.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Helix Biomedix's adjusted free cash flow per share for the three months ended in Sep. 2012 was $-3.084. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Sep. 2012.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-26), Helix Biomedix's current stock price is $1.79. Helix Biomedix's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2012 was $0.00. Helix Biomedix's Cyclically Adjusted Price-to-FCF of today is .


Helix Biomedix  (OTCPK:HXBM) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Helix Biomedix Cyclically Adjusted FCF per Share Related Terms


Helix Biomedix Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Helix Biomedix's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helix Biomedix Cyclically Adjusted FCF per Share Chart

Helix Biomedix Annual Data
Trend Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Helix Biomedix Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HXBM vs XBIO, CBLI, ADYX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Helix Biomedix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix Biomedix Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix Biomedix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Helix Biomedix's Cyclically Adjusted Price-to-FCF falls into.



Helix Biomedix Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Helix Biomedix's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2012 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2012 (Change)*Current CPI (Sep. 2012)
=-3.084/231.4070*231.4070
=-3.084

Current CPI (Sep. 2012) = 231.4070.

Helix Biomedix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200212 274.471 180.900 351.103
200303 -16.171 184.200 -20.315
200306 -18.343 183.700 -23.107
200309 -12.854 185.200 -16.061
200312 -20.438 184.300 -25.662
200403 -18.537 187.400 -22.890
200406 -12.133 189.700 -14.801
200409 -13.244 189.900 -16.139
200412 -13.457 190.300 -16.364
200503 -13.574 193.300 -16.250
200506 -13.482 194.500 -16.040
200509 -12.134 198.800 -14.124
200512 -10.328 196.800 -12.144
200603 -10.100 199.800 -11.698
200606 -11.224 202.900 -12.801
200609 -9.500 202.900 -10.835
200612 -11.500 201.800 -13.187
200703 -9.557 205.352 -10.770
200706 -10.488 208.352 -11.649
200709 -8.616 208.490 -9.563
200712 -9.791 210.036 -10.787
200803 -9.198 213.528 -9.968
200806 -9.186 218.815 -9.715
200809 -17.814 218.783 -18.842
200812 -0.686 210.228 -0.755
200903 -10.791 212.709 -11.740
200906 -8.407 215.693 -9.019
200909 -8.105 215.969 -8.684
200912 -8.407 215.949 -9.009
201003 -7.570 217.631 -8.049
201006 -9.965 217.965 -10.580
201009 -7.651 218.439 -8.105
201012 -6.048 219.179 -6.385
201103 -4.663 223.467 -4.829
201106 -3.554 225.722 -3.644
201109 -3.319 226.889 -3.385
201112 -2.313 225.672 -2.372
201203 -3.163 229.392 -3.191
201206 -2.392 229.478 -2.412
201209 -3.084 231.407 -3.084

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.00 mean?
Helix Biomedix (HXBM) has a Cyclically Adjusted FCF per Share of $0.00 as of Sep. 2012. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Helix Biomedix and its competitors.
Is Helix Biomedix's Cyclically Adjusted FCF per Share too high?
Helix Biomedix's current Cyclically Adjusted FCF per Share is $0.00.
How does Helix Biomedix's Cyclically Adjusted FCF per Share compare to XBIO and CBLI?
Helix Biomedix's Cyclically Adjusted FCF per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Helix Biomedix and its competitors. Helix Biomedix's current Cyclically Adjusted FCF per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix Biomedix stock overvalued right now?
Helix Biomedix (HXBM) has a current Cyclically Adjusted FCF per Share of $0.00. The current Cyclically Adjusted FCF per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Helix Biomedix (HXBM), the current Cyclically Adjusted FCF per Share is $0.00 as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helix Biomedix Business Description

Address 19125 North Creek Parkway, Suite 120, Bothell, WA, USA, 98011
Helix Biomedix Inc is a Delaware-based biopharmaceutical company that focuses on the early-stage development of peptide-based therapeutics for dermatology and skin health. The Company is in the preclinical stage, advancing a rare disease drug program for xeroderma pigmentosum, and plans to seek orphan drug designation before entering clinical development. Leveraging its proprietary peptide technology, Helix BioMedix aims to address unmet needs in rare dermatological conditions and has a history of developing patented bioactive peptides for topical personal care use.